ClinicalTrials.gg
CompletedNCT06377930Updated Feb 5, 2026

Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

A Phase 2 interventional study of RAP-219 in Focal Onset Seizures, sponsored by Rapport Therapeutics Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Rapport Therapeutics Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 395 studies in Seizures with a site in United States — 75 open to participants now, 93 under way, 21 of them phase 3. Seizures · United States.

Enrollment
192nd of 306
30 · median 56
Started
2024
with 19 others
Phase 2
64 of 395
10 open now
Registered
349th of 395
by date

Among the 395 studies in Seizures with a site in United States, this one is the 192nd largest by enrollment of the 306 interventional ones that give a count, is one of 20 that started in 2024, is one of 64 in phase 2, and was the 349th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

75 of the 395 studies in Seizures with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Seizures with a site in United States, or all of them as a file.
02

Study summary

This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.

Read the detailed description

This is a Phase 2A, proof-of-concept, multi-center, open-label study designed to evaluate the efficacy, safety, tolerability, and PK/PD relationship of RAP-219 in adult participants with refractory focal epilepsy. The activity of RAP-219 will be assessed in approximately 30 participants treated with the RNS® system.

03

Conditions studied

  • Focal Onset Seizures

Keywords

  • Epilepsy
  • RNS
  • long episode
  • FOS
  • Refractory focal epilepsy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medically focal epilepsy with an implanted responsive neurostimulator device placed correctly in a seizure onset zone that meet several device-related criteria and demonstrated history of compliance with interrogation of the RNS device and upload of data
  • If currently treated with antiseizure medications, up to a maximum of 4 concomitant mediations are allowed
  • At least 1 clinical seizure during the 8-week retrospective eligibility period
  • Participants in otherwise good health as determined by the investigator
  • Willing and able to adhere to all aspects of the protocol
  • A demonstrated history of compliance with interrogation of the RNS device and upload of data before screening

Exclusion criteria

Exclusion Criteria:

  • Participants with generalized onset seizures in the past 10 years
  • History of status epilepticus while on antiseizure medications within 2 years of screening
  • Individuals of who do not agree to simultaneously use two effective birth-control methods
  • Participants who have had epilepsy surgery within the last 12 months before screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    RAP-219

    Participants will receive 0.75 mg RAP-219 daily for 5 days followed by 1.25 mg RAP-219 daily for the remainder of the 8-week treatment period.

    Drug: RAP-219

Interventions

06

What researchers measure

Primary outcomes

  1. Change in long episode frequency during the treatment period compared to pre-treatment baseline: Responder proportion, Percent Change Percent change

    Change in long episode frequency per 28-day period during the treatment period compared to baseline

    Time frame: Screening until 5 months after enrollment

Secondary outcomes

  1. Change in focal clinical seizure frequency during the treatment period compared to pre-treatment baseline: Percent Change, Responder proportion

    Change in focal clinical seizure frequency per 28-day period during the treatment period compared to baseline

    Time frame: Screening until 5 months after enrollment

  2. Change in frequency of estimated electrographic seizures based on RNS® system data during the treatment period compared to pre-treatment baseline

    Change in the frequency per 28-day period of estimated electrographic seizures based on RNS data during the treatment period compared to baseline

    Time frame: Screening until 5 months after enrollment

  3. Change in RNS® system long episode-free days during the treatment period compared to pre-treatment baseline: Count, Longest continuous interval, Time until pre-treatment count

    Change in long episode-free days during the treatment period compared to pre-treatment baseline

    Time frame: Screening until 5 months after enrollment

  4. Change in focal clinical seizure-free days during the treatment period compared to pre-treatment baseline: Count, Longest continuous interval, Time until pre-treatment count

    Change in focal clinical seizure-free days during the treatment period compared to pre-treatment baseline

    Time frame: Screening until 5 months after enrollment

  5. Change in RNS® system electrographic biomarkers other than long episodes during the treatment period compared to pre-treatment baseline

    Change in RNS® system electrographic biomarkers other than long episodes during the treatment period compared to pre-treatment baseline

    Time frame: Dosing until 5 months after dosing

  6. Change in the Seizure Severity Response Questionnaire (SSRQ) during the treatment period compared to pre-treatment baseline

    Measurement of seizure severity by participant rating scale of the Seizure Severity Scale. Seizure severity will be assessed by asking participants to respond to 4 questions using a 0-10 numerical rating scale and circling the number that best describes how their seizures have impacted them since their last study visit. Higher scores = higher impact.

    Time frame: Screening until 5 months after enrollment

  7. Count and proportion of responders on the clinical global impression of change (CGIC) scale during the treatment period compared to pre-treatment baseline

    Change in overall clinical status as measured by Clinical Global Impression of Change scores rated by investigator and participant. Both the participant (PGIC) and the clinician (CGIC) will rate their global impression of changes in the participant's condition throughout the study. The CGI scale measures the change in the participant's clinical status from a specific point in time, i.e., the Baseline Period and is rated on a 7-point Likert scale ranging from a score of 1 for very much improved to 7 for very much worse. Higher scores = worse outcome.

    Time frame: Screening until 5 months after enrollment

  8. Plasma concentrations of RAP-219

    Analysis of plasma concentrations of RAP-219

    Time frame: Dosing until 5 months after dosing

  9. Incidence of treatment-emergent adverse events (TEAEs)

    Analysis of AEs during the treatment and pre-treatment baseline periods

    Time frame: Dosing until 5 months after enrollment

  10. Clinically meaningful changes, if any, from baseline in vital signs, electrocardiograms (ECGs), complete blood counts, serum chemistries, or liver function tests after treatment with RAP-219

    Analysis of vital signs, ECGs, CBC, serum chemistries and liver function tests during the treatment and pre-treatment baseline periods

    Time frame: Screening until 5 months after enrollment

  11. Incidence of participants expressing suicidal ideation assessed with the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Analysis of C-SSRS entries during the treatment and pre-treatment baseline periods

    Time frame: Screening until 5 months after enrollment

  12. Cognitive function as measured using the Cogstate Digital Battery

    Analysis of the Cogstate Digital Battery during the treatment and pre-treatment baseline periods

    Time frame: Screening until 5 months after enrollment

07

Study locations

12 sites
  • Yale University
    New Haven, Connecticut 06519, United States
  • Consultants in Epilepsy and Neurology, PLLC
    Boise, Idaho 83702, United States
  • IU Health Neuroscience Center, Goodman Hall
    Indianapolis, Indiana 46202, United States
  • The University of Kansas Medical Center Epilepsy Clinic
    Kansas City, Kansas 66160, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • NYU Langone Comprehensive Epilepsy Center
    New York, New York 10016, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Pennsylvania - Department of Neurology
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Baylor College of Medicine
    Houston, Texas 770300, United States
  • University of Texas Health Science Center, Houston
    Houston, Texas 77030, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Sep 2025, 11 months.

Of 35 phase 2 interventional studies under Seizures, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2024
First posted
Apr 22, 2024
StartActual
Oct 10, 2024
Primary completionActual
Sep 26, 2025
CompletionActual
Sep 26, 2025
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06377930
Lead sponsor
Rapport Therapeutics Inc.
Responsible party
Sponsor
First posted
Apr 22, 2024
Start date
Oct 10, 2024
Primary completion
Sep 26, 2025
Completion
Sep 26, 2025
Last update
Feb 5, 2026

Study contacts

Jaqueline A French, MD
principal investigator · NYU Langone Comprehensive Epilepsy Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RAP-219

Start the discussion